New Delhi: In a growth which spells enormous reduction for lakhs of COVID-19 sufferers, the Centre on Saturday (April 17, 2021) slashed costs of the anti-COVID-19 drug Remdesivir by nearly Rs 2,000 per injection.
In a press observe on Saturday, the Ministry of Chemicals Fertilisers, Department of Pharmaceuticals, Member Advisor Dr Vinod Kotwal issued a brand new checklist with the revised costs.
The anti-viral drug will now be bought for as much less as Rs 899.
The revised price charges are as follows:
1. Cadila Healthcare Ltd REMDAC from 2,800/- to 899/-Â
2. Syngene International Ltd (Biocon Biologics India) RemWin from 3,950/- to 2,450/-
3. Dr. Reddy’s Laboratories Ltd REDYX from 5,400/- to 2,700/-
4. Cipla Ltd CIPREMI from 4,000/- to three,000/-
5. Mylan Pharmaceuticals Pvt Ltd DESREM from 4,800/- to three,400/-
6. Jubilant Generics Ltd JUBI-R from 4,700/- to three,400/-
7. Hetero Healthcare Ltd COVIFOR from 5,400/- to three,490/-Â
As India battles second wave of coronavirus, the producers of the injection have slashed the price amid the scarcity of the anti-viral drug Remdesivir. The announcement after the Centre held a gathering with all-existing producers of the drug to debate the rise in manufacturing and provide and likewise to scale back the price of Remdesivir injection.
As India experiences a second wave of novel coronavirus infections, the demand for anti-viral drug Remdesivir has surged. The Centre on April 11 banned the export of Remdesivir and its lively pharmaceutical substances.
“In light of the above, Government of India has prohibited the exports of Injection Remdesivir and Remdesivir Active Pharmaceutical Ingredients (API) till the situation improves,” the well being ministry stated in an announcement. As many as seven Indian corporations have licensed the drug from US-based Gilead Sciences, with an put in capability of about 3.9 million models per thirty days.
